

In the Claims

Kindly amend claims 1-36 as follows. Add new claim 37.

1. (Currently Amended) A method for treatment or prevention of snoring, sleep apnea or sudden infant death syndrome and for improvement of nasal breathing in mammals, said method comprising a step of administering to a subject in need thereof nasally or pharyngeally a liquid or a solid composition consisting ~~essentially~~ of from about 0.01 to about 20% an alkylaryl polyether alcohol polymer alone or in admixture with a pharmaceutically acceptable excipient, diluent or both ~~nasally or pharyngeally~~.

2. (Previously Amended) The method of claim 1, wherein said composition is applied from antegrade or from retrograde.

3. (Original) The method of claim 1, wherein the alkylaryl polyether alcohol polymer is tyloxapol.

4. (Previously Amended) The method of claim 3 wherein the composition is formulated as a nasal or pharyngeal spray, as a nasal solution, as a dry powder, as a lozenge or as a nasal aerosol.

5. (Currently Amended) The method of claim 4 useful for treatment and prevention of snoring in humans comprising ~~administration of the composition consisting~~ of from about 0.2 to about 20% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

6. (Currently Amended) The method of claim 5 ~~wherein the composition is consisting~~ comprising administration of from about 1 to about 10% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

7. (Previously Amended) The method of claim 6 wherein the composition is formulated as the nasal or pharyngeal spray.

8. (Currently Amended) The method of claim 7 ~~wherein the composition is consisting~~ comprising administration of about 1% 10 mg of tyloxapal in admixture with about 50 mg of glycerol and 20 mg of sodium bicarbonate.

9. (Currently Amended) The method of claim 4 useful for treatment and prevention of sleep apnea in humans comprising administration of ~~the composition consisting of~~ from about 0.5 to about 20% of tyloxapal alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

10. (Currently Amended) The method of claim 9 ~~wherein the composition is consisting~~ comprising administration of from about 5 to about 15% of tyloxapal alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

11. (Previously Amended) The method of claim 10 wherein the composition is formulated as the nasal or pharyngeal spray.

12. (Currently Amended) The method of claim 11 ~~wherein the composition is consisting~~ comprising administration of about 5% of tyloxapal alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

13. (Currently Amended) The method of claim 4 useful for treatment and prevention of sudden infant death syndrome in infants comprising administration ~~of the composition consisting of~~ from about 0.01 to about 5% of tyloxapal alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

14. (Currently Amended) The method of claim 13 ~~wherein the composition is consisting~~ comprising administration of from about 0.1 to about 2% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

15. (Previously Amended) The method of claim 14 wherein the composition is formulated as the nasal spray or nasal solution.

16. (Currently Amended) The method of claim 15 ~~wherein the composition consisting~~ comprising administration of about 0.1% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both ~~is administered to an infant before sleep~~ in 1-3 drops solution to an infant before sleep.

17. (Currently Amended) The method of claim 4 useful for improvement of nasal breathing in humans comprising administration ~~of the composition consisting~~ of from about 0.2 to about 20% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

18. (Currently Amended) The method of claim 17 useful for improvement of nasal breathing during physical activity or for improvement of nasal breathing impaired due to a disease, infection or surgery by administering to a subject in need of such treatment the composition consisting of from about 0.5 to about 10% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

19. (Currently Amended) The method of claim 18 wherein the physical activity is diving, mountain hiking, high altitude mountain climbing or flying and wherein the composition is formulated as the nasal or pharyngeal spray, drops or lozenge.

20. (Currently Amended) The method of claim 19 wherein the ~~composition consisting of about 1% of tyloxapol is formulated as~~ nasal drops, spray or lozenge contain about 1% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

21. (Original) The method of claim 4 useful for improvement of nasal breathing in animals.

22. (Currently Amended) The method of claim 21 wherein the treatment for improvement of nasal breathing in animals comprises administration of the nasal spray ~~composition~~ consisting of from about 0.2 to about 20% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

23. (Currently Amended) The method of claim 22 ~~wherein the composition is consisting~~ comprising administration of from about 5 to about 15% of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

24. (Currently Amended) The method of claim 1 wherein ~~the said composition consisting of~~ contains from about 10 mg 1% to about 10% of the alkylaryl polyether alcohol polymer, and additionally comprises 50 mg glycerol, and 20 mg sodium bicarbonate dissolved in an aqueous solution or in normal or diluted saline.

25. (Currently Amended) A device for administration of a nasal or pharyngeal composition consisting ~~essentially~~ of from about 0.01 to 20% of alkylaryl polyether alcohol polymer alone or in admixture with a pharmaceutically acceptable excipient, diluent or both, said device suitable for administration of said composition for treatment and prevention of snoring, sleep apnea,

sudden infant death syndrome or for improvement of nasal breathing.

26. (Currently Amended) The device of claim 25 wherein ~~the~~ said device is a spray container, spray vial, spray pump, atomizer, nebulizer, aerosolizer, dry powder inhaler, humidifier or a mask.

27. (Original) The device of claim 26 wherein the mask is a nasal mask suitable for application of continuous positive airway pressure.

28. (Previously Amended) The device of claim 26, wherein the device is a spray container suitable for administration of the composition to a nasal or upper pharyngeal mucosa using an extension nozzle.

29. (Previously Amended) The device of claim 28 wherein the composition is formulated as a dry powder and the device is the dry powder inhaler.

30. (Currently Amended) A nasal or pharyngeal composition for treatment or prevention of snoring, sleep apnea, sudden infant death syndrome and improvement of nasal breathing in mammals, consisting ~~essentially~~ of from about 0.1 mg to about 200 mg of an alkylaryl polyether alcohol polymer alone or in combination with another alkylaryl polyether alcohol polymer, said alkylaryl polyether alcohol polymer or the combination further in admixture with a pharmaceutically acceptable excipient, or additive or diluent.

31. (Currently Amended) The composition of claim 30, wherein ~~the~~ at least one alkylaryl polyether alcohol polymer is tyloxapol and the composition is formulated as a nasal spray, nasal solution,

nasal drops, lozenge or dry powder.

32. (Currently Amended) The composition of claim 31 wherein tyloxapol is present in concentration from about 1 mg to about 100 mg dissolved in a distilled water or in a normal or diluted saline.

33. (Currently Amended) The composition of claim 32 wherein said diluted saline is quarter normal or half normal saline.

34. (Currently Amended) The composition of claim 31, formulated as ~~a~~ the dry powder or lozenge.

35. (Original) The composition of claim 34 formulated as the dry powder having a particle size between 5 and 100 microns.

36. (Original) The composition of claim 34 formulated as the lozenge.

37. (New) The composition of claim 30 wherein said alkylaryl polyether alcohol polymer or the combination is further in admixture with another pharmacologically active compound selected from the group consisting of antibiotics, anti-inflammatories and analgesics.